Infliximab for the treatment of pediatric ulcerative colitis

Gia M. Bradley, Maria Oliva-Hemker

Research output: Contribution to journalReview articlepeer-review


Ulcerative colitis is a chronic, idiopathic, inflammatory disease of the colon and rectum that may be associated with growth failure, nutritional derangements and psychosocial ramifications in affected children. Multiple medical options are available to achieve disease remission; however, some of these medications can have unwanted side effects, especially in younger patients. With increased understanding of the etiology of the disease, newer therapeutic alternatives have arisen in the form of biologic therapies, namely monoclonal antibodies targeted to a specific protein or receptor. Specifically, infliximab, an anti-TNF-α agent, has been shown to be safe and effective for the treatment of moderate-to-severe pediatric ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)659-665
Number of pages7
JournalExpert Review of Gastroenterology and Hepatology
Issue number6
StatePublished - Dec 2012


  • anti-TNF-α agents
  • inflammatory bowel disease
  • infliximab
  • ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Infliximab for the treatment of pediatric ulcerative colitis'. Together they form a unique fingerprint.

Cite this